Novartis Phase III Trial Examining EPO906 (patupilone) For Patients With Advanced Ovarian Cancer Failed To Meet Primary Endpoint

Links shared publicly online about this topic.

  • 1,126
    total visits

Novartis Phase III Trial Examining EPO906 (patupilone) For Patients With Advanced Ovarian Cancer Failed To Meet Primary Endpoint

medicalnewstoday.com —

Novartis announced that patupilone (EPO906) did not show a significant overall survival advantage in a phase III trial of patients with advanced ovarian cancer, refractory or resistant to platinum

View full resource at medicalnewstoday.com

Tags: Cancer, Ovarian Cancer, Women's Health, Novartis

  • Share

Most Recently Shared on June 1, 2010 at 11:19 pm By:

mnt_pharma MNT Pharma News

Novartis Phase III Trial Examining EPO906 (patupilone) For Patients With Advanced Ovarian Cancer Failed To Meet Primar... http://mnt.to/3DkL

2 years ago...

Reply

Retweet

Favorite

Also Shared By:

MNT Ovarian Cancer MNT Ovarian Cancer

Ovarian Cancer OW Ovarian Cancer OW

MNT Clinical Trials MNT Clinical Trials

Advertisement